CAS 130209-82-4PubChem CID 5311221
Latanoprost
- IUPAC name
- propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
- Molecular formula
- C26H40O5
- Molecular weight
- 432.6 g/mol
- Exact mass
- 432.28757437 Da
- XLogP3
- 4.3
- Topological polar surface area
- 87.0 Ų
- Hydrogen-bond donors
- 3
- Hydrogen-bond acceptors
- 5
- Covalent units
- 1
- Defined stereocentres
- 5
Also known as
XalatanPhXA41PHXA-41XA41PhXA 41XA-41IYUZEHlatanoprost (isopropyl ester)
16 more reported names
latanoprostum6Z5B6HVF6OXELPROSIsopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoateT-2345CHEBI:6384propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoateT2345XALACOM COMPONENT LATANOPROSTpropan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoateLatanoprost PF5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1-alpha(Z),2-beta(R*),3-alpha,5-alpha))-Monopostisopropyl (z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoatepropan-2-yl (5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoatepropan-2-yl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
External database identifiers
- ChEBI:CHEBI:6384
- ChEMBL:CHEMBL1051
- EPA DTXSID:DTXSID1041057
- PubMed:29921209
- PubMed:25811541
- PubMed:25328381
- PubMed:23956101
- PubMed:20019365
- PubMed:19403113
- PubMed:18721251
- PubMed:18166407
- PubMed:17539800
- PubMed:17459480
- PubMed:17416939
- PubMed:17102001
Evidence from additional scientific databases
NIH PubChem PUG-View
Exact identifier match5311221
Attributed physical-property, hazard, environmental and use annotations.
- Boiling Point: 583.8 Source: DrugBank
- pKa: 4.88 Source: DrugBank
- LogP: 3.98 Source: DrugBank
- LogP: 4.4 Source: Human Metabolome Database (HMDB)
- Physical Description: Liquid Source: Human Metabolome Database (HMDB)
- Solubility: 1.29e-02 g/L Source: Human Metabolome Database (HMDB)
- Note: This chemical does not meet GHS hazard criteria for 0.7% (1 of 145) of reports. Source: European Chemicals Agency (ECHA)
- Signal: Danger Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H300 (63.4%): Fatal if swallowed [Danger Acute toxicity, oral]; H301 (11%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (62.1%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] Source: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 145 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 1 of 145 reports by companies.; There are 15 notifications provided by 144 of 145 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
- Toxicity Summary: Researchers found no carcinogenesis or mutagenesis with latanoprost, and the drug did not affect fertility in animal studies. However, latanoprost was noted to cause a chromosomal aberration in treated human lymphocytes. Intravenous infusion of 3 μg/kg of latanoprost in healthy volunteers produced plasma concentrations 200 times higher than during clinical treatment with latanoprost ophthalmic solution, and researchers identified no ADR. There is no evidence to establish a correlation between latanoprost administration and ocular or cutaneous melanoma.; Intravenous infusion of 5.5 to 10 μg/kg resulted in fatigue, sweating, dizziness, nausea, and abdominal pain. According to the manufacturer's labeling, treatment should be symptomatic if there is an overdosage with latanoprost ophthalmic solution. Source: StatPearls
- Uses: Use (kg) in USA (2002): 1; Consumption (g per capita) in the USA (2002): 3.3e-06; Calculated removal (%): 100 Source: NORMAN Suspect List Exchange
Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record
Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.
Additional source coverage and match status
| Source | Result | Checked |
|---|---|---|
| NIH PubChem PUG-View | Exact match | 2026-08-31 |
A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.